People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akriveia Therapeutics, LLC | — | Biotechnology | Series A | $7.5M | $108.5M | 2016 |
| Duet Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $200K | $2.4M | 2022 |
Simon Tomlinson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simon Tomlinson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Beck | 1 | 7 |
| David Grayzel | 1 | 6 |
| Michael Gladstone | 1 | 3 |
| Benjamin Auspitz | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.